BridgeBio Pharma (BBIO) Leases (2020 - 2026)

BridgeBio Pharma's Leases history runs 7 years deep, the most recent figure standing at $17.2 million for Q1 2026.

• In Q1 2026, Leases rose 140.39% year-over-year to $17.2 million; the TTM figure through Mar 2026 stood at $17.2 million (up 140.39% YoY), while the FY2025 annual figure was $8.1 million, up 41.3% from the prior year.
• Leases came in at $17.2 million for Q1 2026 at BridgeBio Pharma, up from $8.1 million in the prior quarter.
• In the past five years, Leases ranged from a high of $17.2 million in Q1 2026 to a low of $5.8 million in Q4 2024.
• A 5-year average of $9.4 million and a median of $8.1 million in 2025 frame the typical range for Leases.
• Across the five-year window, Leases sank 32.87% in 2022 and surged 140.39% in 2026, its largest moves.
• BridgeBio Pharma's Leases stood at $10.7 million in 2022, then retreated by 24.83% to $8.0 million in 2023, then fell by 28.15% to $5.8 million in 2024, then jumped by 41.3% to $8.1 million in 2025, then soared by 111.39% to $17.2 million in 2026.
• According to Business Quant data, Leases over the past three periods registered $17.2 million, $8.1 million, and $6.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison